Vir Biotechnology (VIR): next trial readout expected around 2026-09-25
$VIR · Vir Biotechnology, Inc.Trials that could report in the next 12 months: 3BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything VIR is running — see methodology.
- 2026-09-25in 5wEffect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
- 2026-12-31in 19wA Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
- 2027-09-29in 58wSafety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-50… | Phase 1 | Recruitingstill enrolling patients | 2027-09-29 | NCT05997615 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase 3 | Active Not Recruitingenrolled, still running | 2026-12-31 | NCT06903338 |
| Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR… | Phase 1 | Recruitingstill enrolling patients | 2026-09-25 | NCT05484206 |
| To Access the Safety and Effects of Intravenous Administration of VIR-… | Phase 1 | Recruitingstill enrolling patients | NCT05356741 | |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D… | Phase 2 | Active Not Recruitingenrolled, still running | NCT05461170 | |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizum… | Phase 1 | Recruitingstill enrolling patients | NCT06960395 | |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic … | Phase 3 | Active Not Recruitingenrolled, still running | NCT07128550 | |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic… | Phase 2 | Active Not Recruitingenrolled, still running | NCT07142811 |
Status-change history
Every ClinicalTrials.gov change recorded for VIR's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is VIR's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is VIR's lead program in?
Phase 3 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.